Edition:
United States

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

8.95USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$8.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,689
52-wk High
$13.30
52-wk Low
$4.10

Chart for

About

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is... (more)

Overall

Beta: 2.13
Market Cap(Mil.): $147.33
Shares Outstanding(Mil.): 12.74
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics

* MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2yOHuTW) Further company coverage:

Dec 08 2017

BRIEF-Trillium announces private placement to fund development of cancer drugs

* Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​

Nov 15 2017

BRIEF-Trillium Therapeutics reports Q3 results

* Trillium Therapeutics reports third quarter 2017 financial and operating results

Nov 10 2017

BRIEF-Trillium provides update on small molecule programs

* Trillium says concluded that TTI-2341 appears to be a viable and competitive drug candidate for treatment of brain cancers and brain metastases

Jul 05 2017

Earnings vs. Estimates